Sarcoidosis - Pipeline Insight, 2024

Sarcoidosis - Pipeline Insight, 2024

DelveInsight’s, Sarcoidosis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Sarcoidosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sarcoidosis Understanding

Sarcoidosis: Overview

Sarcoidosis is a multisystem disorder of unknown etiology characterized by the presence of noncaseating granulomas in organs. This condition mostly affects young adults and characteristically presents with reticular opacities in the lungs and bilateral hilar lymphadenopathy. Other involved sites include eyes, skin, and joints, and in some cases, the reticuloendothelial system, musculoskeletal system, exocrine glands, heart, kidney, and central nervous system. This activity outlines the evaluation and management of sarcoidosis and explains the role of the interprofessional team in improving care for patients with this condition. It is an inflammatory disease of unknown etiology that manifests as noncaseating granulomas in multiple systems. Various associations have been described, including occupational and environmental exposures to beryllium, dust, and other agents causing asthma. Various microorganisms like mycobacteria and propionibacteria have been associated. Possible infective etiology has been described in a few studies where sarcoidosis developed in a previously negative individual after cardiac or bone marrow transplantation.

Pathogenesis of cutaneous sarcoidosis is poorly understood and attributable to both genetic and environmental factors. A key role in the development of sarcoidosis is played by T cells as they promote cellular immune reaction and are usually associated with an inverted CD4/CD8 ratio. It is well characterized by noncaseating granuloma typically containing macrophages, multinucleated giant cells, and epithelioid cells, in addition to lymphocytes, monocytes, mast cells, and fibroblasts. There is a role of tumor necrosis factor (TNF) and TNF receptors, as both are increased in this disease. This has been evidenced by the role of anti-TNF agents, such as pentoxifylline and infliximab. In addition to T cell's role, B cell hyperreactivity with immunoglobulin production is implicated as well. Active sarcoidosis has also been associated with plasmatic hypergammaglobulinemia.Angiotensin-converting enzyme (ACE) levels correlated with elevated soluble HLA class I antigens levels in serum.

""Sarcoidosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sarcoidosis pipeline landscape is provided which includes the disease overview and Sarcoidosis treatment guidelines. The assessment part of the report embraces, in depth Sarcoidosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcoidosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Sarcoidosis. The therapies under development are focused on novel approaches to treat/improve Sarcoidosis.

This segment of the Sarcoidosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

In August 2021, AdVita Lifescience subsidiary of Relief Therapeutics has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis.

Sarcoidosis Emerging Drugs

• RLF-100: Relief Therapeutics

RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients.

• Efzofitimod: aTyr Pharma

Efzofitimod is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. Efzofitimod works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. aTyr is initially investigating efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause progressive fibrosis of the lung.

Further product details are provided in the report……..

Sarcoidosis: Therapeutic Assessment

This segment of the report provides insights about the Sarcoidosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Sarcoidosis

There are approx. 15+ key companies which are developing the therapies Sarcoidosis. The companies which have their Sarcoidosis drug candidates in the most advanced stage, i.e Phase II include,Novartis.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sarcoidosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sarcoidosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sarcoidosis drugs.

Sarcoidosis Report Insights

• Sarcoidosis Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sarcoidosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sarcoidosis drugs?
• How many Sarcoidosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sarcoidosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sarcoidosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sarcoidosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Relief Therapeutics Holdings
• aTyr Pharma
• Amgen
• Bristol-Myers Squibb
• Novartis
• Pfizer
• United Therapeutics Corporation

Key Products

• H3B 6527
• Efzofitimod
• Namilumab
• Abatacept
• CMK 389
• Canakinumab
• Tofacitinib
• Treprostinil